[go: up one dir, main page]

PE20230381A1 - Proteina de union a rgma - Google Patents

Proteina de union a rgma

Info

Publication number
PE20230381A1
PE20230381A1 PE2022001997A PE2022001997A PE20230381A1 PE 20230381 A1 PE20230381 A1 PE 20230381A1 PE 2022001997 A PE2022001997 A PE 2022001997A PE 2022001997 A PE2022001997 A PE 2022001997A PE 20230381 A1 PE20230381 A1 PE 20230381A1
Authority
PE
Peru
Prior art keywords
binding protein
rgma binding
seq
chain variable
variable region
Prior art date
Application number
PE2022001997A
Other languages
English (en)
Inventor
Motonori Hashimoto
Toshihide Yamashita
Original Assignee
Mitsubishi Tanabe Pharma Corp
Univ Chiba Nat Univ Corp
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Univ Chiba Nat Univ Corp, Univ Osaka filed Critical Mitsubishi Tanabe Pharma Corp
Publication of PE20230381A1 publication Critical patent/PE20230381A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Un anticuerpo anti-RGMa aislado o un fragmento de union a antigeno del mismo, en el que la region variable de cadena pesada (VH) comprende lo siguiente: VH: EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAEIRSKANNHATYYAESVKGRFTISRDDSKSIVYLQMNSLRTEDTALYYCTRRDGAYWGKGTTVTVSS (SEQ ID NO: 41); y en el que la region variable de cadena ligera (VL) comprende lo siguiente: VL:DIQMTQSPSSVSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTLPWTFGGGTKVEME (SEQ ID NO: 42).
PE2022001997A 2015-04-28 2016-04-27 Proteina de union a rgma PE20230381A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015091095 2015-04-28
PCT/JP2016/063166 WO2016175236A1 (ja) 2015-04-28 2016-04-27 ＲＧＭａ結合タンパク質及びその使用

Publications (1)

Publication Number Publication Date
PE20230381A1 true PE20230381A1 (es) 2023-03-06

Family

ID=57198582

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022001997A PE20230381A1 (es) 2015-04-28 2016-04-27 Proteina de union a rgma
PE2017002320A PE20180251A1 (es) 2015-04-28 2016-04-27 PROTEINA DE UNIION A RGMa Y SU USO

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017002320A PE20180251A1 (es) 2015-04-28 2016-04-27 PROTEINA DE UNIION A RGMa Y SU USO

Country Status (33)

Country Link
US (3) US10287346B2 (es)
EP (2) EP3290441B1 (es)
JP (7) JP6497760B2 (es)
KR (4) KR102613528B1 (es)
CN (2) CN113801225A (es)
AU (2) AU2016253886B2 (es)
CA (1) CA2983898A1 (es)
CL (1) CL2017002729A1 (es)
CO (1) CO2017011975A2 (es)
CR (2) CR20200517A (es)
CY (1) CY1122569T1 (es)
DK (1) DK3290441T3 (es)
DO (1) DOP2017000248A (es)
ES (1) ES2758480T3 (es)
GT (1) GT201700224A (es)
HR (1) HRP20192099T1 (es)
HU (1) HUE047146T2 (es)
IL (2) IL287291B (es)
LT (1) LT3290441T (es)
MX (2) MX392169B (es)
NZ (2) NZ775372A (es)
PE (2) PE20230381A1 (es)
PH (1) PH12017501941A1 (es)
PL (1) PL3290441T3 (es)
PT (1) PT3290441T (es)
RS (1) RS59847B1 (es)
RU (1) RU2705304C2 (es)
SA (1) SA517390230B1 (es)
SG (1) SG11201708848TA (es)
SI (1) SI3290441T1 (es)
TW (4) TWI873576B (es)
WO (1) WO2016175236A1 (es)
ZA (2) ZA201708047B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102613528B1 (ko) * 2015-04-28 2023-12-12 미쓰비시 타나베 파마 코퍼레이션 RGMa 결합 단백질 및 그 사용
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP6709345B1 (ja) 2017-05-25 2020-06-10 シグニファイ ホールディング ビー ヴィＳｉｇｎｉｆｙ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 照明器具
US20210269516A1 (en) 2018-07-10 2021-09-02 Mitsubishi Tanabe Pharma Corporation Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
CN112566664B (zh) * 2018-07-19 2023-08-25 国立大学法人东京大学 Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法
AR120898A1 (es) * 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
WO2021145432A1 (ja) 2020-01-15 2021-07-22 国立大学法人大阪大学 糖尿病性自律神経障害の予防又は治療剤
US20230090965A1 (en) * 2020-01-15 2023-03-23 Osaka University Prophylactic or therapeutic agent for dementia
CN112138146B (zh) * 2020-09-25 2022-08-09 安徽医科大学 Manf蛋白的应用
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
EP4616866A1 (en) 2022-11-07 2025-09-17 The University of Osaka Agent for preventing or treating disease associated with accumulation of abnormal protein aggregates
WO2025070749A1 (ja) * 2023-09-29 2025-04-03 田辺三菱製薬株式会社 脊髄又は脳の障害により引き起こされる疾患に伴う随伴症状の予防又は治療剤

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5565331A (en) 1993-11-12 1996-10-15 The Regents Of The University Of California Nucleic acids encoding neural axon outgrowth modulators
US5747262A (en) 1995-10-16 1998-05-05 The Regents Of The University Of California Neurological drug screens
US5824775A (en) 1996-04-19 1998-10-20 The Regents Of The University Of California Human netrin-1
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
JP2001515018A (ja) 1997-08-13 2001-09-18 エール ユニバーシティ 中枢神経軸索再生
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO2000032746A2 (en) 1998-11-30 2000-06-08 Millennium Pharmaceuticals, Inc. Netrin-like and ependymin-like nucleic acids and polypeptides and uses thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US20030103945A1 (en) 2001-02-09 2003-06-05 Chen Dong Feng Methods and compositions for stimulating axon regeneration and preventing neuronal cell degeneration
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7319138B2 (en) 2002-04-18 2008-01-15 The General Hospital Corporation Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
WO2004003150A2 (en) * 2002-06-26 2004-01-08 Yale University Modulators and modulation of the interacton between rgm and neogenin
US20040199186A1 (en) 2003-04-04 2004-10-07 Kuffler Suzanne Elizabeth Implant to promote axon regeneration across spinal cord and peripheral nerve gaps
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
US20070253946A1 (en) 2004-03-11 2007-11-01 Bioclues, Inc. Axon Regeneration Promoter
CN1950108A (zh) * 2004-03-11 2007-04-18 生物线索株式会社 轴突再生促进剂
AU2005275062A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7449442B2 (en) 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
CA2624562A1 (en) * 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
US20080051319A1 (en) 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting JNK Signaling Promotes CNS Axon Regeneration
WO2008038599A1 (en) 2006-09-25 2008-04-03 National University Corporation Chiba University Axonal regeneration promoter
EP1906185A1 (en) 2006-09-26 2008-04-02 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
DE102008014880A1 (de) 2008-03-12 2009-09-17 Eberhard-Karls-Universität Tübingen Antientzündliches Polypeptid
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN101306193A (zh) 2008-05-15 2008-11-19 复旦大学 人神经突起生长素在制备创伤愈合药物中的应用
AU2009255973B2 (en) 2008-06-06 2013-08-15 Children's Medical Center Corporation Promoting axon regeneration in the adult CNS through control of protein translation
JP2010146801A (ja) * 2008-12-17 2010-07-01 Kurita Water Ind Ltd 微生物発電方法及び微生物発電装置
US9175075B2 (en) * 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
EP2510948B1 (en) 2009-12-09 2015-09-09 Mitsubishi Tanabe Pharma Corporation T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance
AU2012352168C1 (en) * 2011-12-14 2018-01-25 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
AU2013211939C1 (en) * 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013113107A1 (en) 2012-02-03 2013-08-08 University Health Network Methods for promoting neuron survival, axonal growth and/or regeneration
GB201203180D0 (en) * 2012-02-24 2012-04-11 Okapi Sciences Nv Compounds for treating parvovirus infection
US20140242043A1 (en) 2013-02-23 2014-08-28 Stemnion, Inc. Methods for preventing or treating optic neuritis
AU2014238546C1 (en) * 2013-03-18 2019-01-17 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
MX2016003525A (es) 2013-09-17 2017-01-06 Univ Health Network (Uhn) Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento.
US11485787B2 (en) 2014-02-05 2022-11-01 Dana-Farber Cancer Institute, Inc. Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
KR102613528B1 (ko) * 2015-04-28 2023-12-12 미쓰비시 타나베 파마 코퍼레이션 RGMa 결합 단백질 및 그 사용
CN105925578A (zh) 2016-05-30 2016-09-07 东北师范大学 靶向沉默Neogenin的shRNA
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multi-specific immune targeting molecules and uses thereof

Also Published As

Publication number Publication date
NZ775372A (en) 2024-12-20
JP2023120374A (ja) 2023-08-29
IL255293A0 (en) 2017-12-31
HRP20192099T1 (hr) 2020-03-06
GT201700224A (es) 2019-07-26
JP2021106587A (ja) 2021-07-29
AU2016253886A1 (en) 2017-12-14
CN113801225A (zh) 2021-12-17
HUE047146T2 (hu) 2020-04-28
CL2017002729A1 (es) 2018-06-08
RS59847B1 (sr) 2020-02-28
ES2758480T3 (es) 2020-05-05
JP7606196B2 (ja) 2024-12-25
PH12017501941A1 (en) 2018-03-19
KR20170138565A (ko) 2017-12-15
JP2023025285A (ja) 2023-02-21
KR20190124350A (ko) 2019-11-04
EP3290441A4 (en) 2018-10-17
KR102040235B1 (ko) 2019-11-05
RU2705304C2 (ru) 2019-11-06
CO2017011975A2 (es) 2018-02-20
JP6497760B2 (ja) 2019-04-10
TW202138389A (zh) 2021-10-16
IL255293B (en) 2021-10-31
JP7306660B2 (ja) 2023-07-11
RU2019134410A (ru) 2020-03-03
ZA201907773B (en) 2021-05-26
TW202328205A (zh) 2023-07-16
TW202521584A (zh) 2025-06-01
SI3290441T1 (sl) 2020-03-31
LT3290441T (lt) 2020-02-10
RU2017135353A3 (es) 2019-04-08
WO2016175236A1 (ja) 2016-11-03
TWI732757B (zh) 2021-07-11
US20210277098A1 (en) 2021-09-09
CR20200517A (es) 2021-01-12
MX2022005565A (es) 2022-06-09
KR102451786B1 (ko) 2022-10-05
CY1122569T1 (el) 2021-01-27
MX2017013894A (es) 2018-03-01
EP3290441A1 (en) 2018-03-07
CN107531791A (zh) 2018-01-02
JP7307446B2 (ja) 2023-07-12
PT3290441T (pt) 2019-12-02
JP6955721B2 (ja) 2021-10-27
US20190270799A1 (en) 2019-09-05
NZ775384A (en) 2024-12-20
US11008388B2 (en) 2021-05-18
SA517390230B1 (ar) 2021-06-09
US20180100012A1 (en) 2018-04-12
PE20180251A1 (es) 2018-02-02
HK1245808A1 (en) 2018-08-31
CR20170539A (es) 2018-04-20
JP2025029166A (ja) 2025-03-05
JP2019141048A (ja) 2019-08-29
KR102613528B1 (ko) 2023-12-12
BR112017022994A2 (pt) 2019-11-19
KR20230173734A (ko) 2023-12-27
MX392169B (es) 2025-03-21
KR102854388B1 (ko) 2025-09-02
TWI873576B (zh) 2025-02-21
JP2023030057A (ja) 2023-03-07
ZA201708047B (en) 2020-01-29
EP3584260A1 (en) 2019-12-25
IL287291B (en) 2022-09-01
CN107531791B (zh) 2021-09-07
TW201710296A (zh) 2017-03-16
PL3290441T3 (pl) 2020-05-18
DK3290441T3 (da) 2020-01-02
IL287291A (en) 2021-12-01
DOP2017000248A (es) 2018-01-31
TWI873350B (zh) 2025-02-21
SG11201708848TA (en) 2017-11-29
JP7780158B2 (ja) 2025-12-04
US10287346B2 (en) 2019-05-14
EP3290441B1 (en) 2019-10-30
RU2017135353A (ru) 2019-04-08
KR20220140023A (ko) 2022-10-17
NZ737770A (en) 2024-09-27
CA2983898A1 (en) 2016-11-03
AU2016253886B2 (en) 2019-05-16
AU2019210655A1 (en) 2019-08-22
JPWO2016175236A1 (ja) 2018-04-19

Similar Documents

Publication Publication Date Title
PE20230381A1 (es) Proteina de union a rgma
CU24568B1 (es) Anticuerpo inhibidor de masp-3
MX2025002735A (es) Virus oncolitico que codifica un inhibidor de la molecula 4 asociada a linfocitos t citotoxicos (ctla-4) y su uso en el tratamiento de cancer
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
CR20170026A (es) Anticuerpos anti-tau humanizados
MX2020000960A (es) Anticuerpos anti-tigit.
AR105267A1 (es) Anticuerpos de unión a tau
MX2019013387A (es) Dominio de union a antigeno.
PE20190737A1 (es) Anticuerpos anti-cd27
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
ECSP17012781A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
MY195993A (en) Antibodies and Antibody Fragments for Site-Specific Conjugation
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
MX377716B (es) Moduladores de aplnr y usos de estos.
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
CO2019002369A2 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
CO2019002370A2 (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo
CO2017004753A2 (es) Anticuerpos que se unen a ccr6